Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalent will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company's consumer health and biomodalities unit, the company said late Monday.

Catalent delays quarterly filing with SEC on $700 mln impairment charge

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Catalent (CTLT) Q1 Earnings Expected to Decline

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release preliminary financial results for the first quarter of fiscal year 2024 ended September 30, 2023, before the market open on Wednesday, November 15, 2023. Catalent's management will host a webcast to discuss the preliminary results at 8:15 a.m. ET on the same day. Catalent invites all interested parties t.

Catalent, Inc. Announces First Quarter Fiscal Year 2024 Earnings Conference Webcast

Arista Networks

Carnival

Chipotle

Centene

Dollar General

Intel

NVIDIA

Warner Bros Discovery Inc

Zions Bancorp

The S&P 500 just dropped for the third straight month — clobbering most S&P 500 investors. But there's still plenty of ways to profit.

10 Stocks Turn $10,000 Into $158,688 In 10 Months

Avantor Inc.

Danaher

DexCom

Inspire Medical Systems Inc

Coca-Cola

Eli Lilly

Novo Nordisk

PepsiCo

Insulet

Repligen

Thermo Fisher Scientific

Walmart

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same period.

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported a 3% increase in revenue for the quarter-ended June 2023, but Biologics revenue was down 37% year-over-year. Catalent's margins have weakened, with gross profit down 49% year-over-year and EBITDA down over 90% year-over-year.

Catalent Remains Overvalued

Valero Energy

Stocks tanked right on cue in September. But nimble S&P 500 investors are still finding ways to make big money.

9 Stocks Turn $10,000 Into $141,941 In 9 Months

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced it recently entered into an exclusive development and license agreement with Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities. Under the terms of the agreement, Melt Pharmaceuticals will utilize Catalent's proprietary Zydis® orally disintegrating tablet (ODT) f.

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent's Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza's Bioscience business. Prior to joining Lonza, Mr. McErlane held several leadership positions at M.

Catalent Appoints David McErlane as Biologics Segment Leader

Elliott recently entered a cooperation agreement with Catalent. This could pave the way for some major changes at the pharmaceutical company.

Activist Elliott makes inroads at Catalent to build value. Here's what could happen next

Drug manufacturer Catalent Inc. CTLT, +1.74% said Friday it has received a notice from the New York Stock Exchange informing it that's it's not in compliance with listing rules due to a delay in filing its annual form 10-K with the Securities and Exchange Commission. The company has six months from Sept.

Catalent gets NYSE notice that it's not in compliance with listing rules over late 10-K filing

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, on September 14, 2023, it received a notice (the “NYSE Notice”) from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manu.

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Advance Auto Parts

Bio-Rad Laboratories

Estee Lauder

Enphase Energy

Etsy

KeyCorp

MarketAxess Holdings

Mosaic

Moderna

Newell Brands

Paramount Global

ResMed

SolarEdge Technologies

Sealed Air

Walgreens

Window dressing is a deceitful practice where mutual funds and other large institutions buy high-flying stocks and sell off the losing ones just before the end of a quarter, when many funds must report their holdings.

These Stocks Could Face Selling Pressure Soon

International Flavors & Fragrances

Stanley Black & Decker

S&P 500 companies collectively saw second-quarter earnings fall by 4% over last year. A big problem for the index constituents is the higher interest expenses that are eating into corporate profits.

3 Debt-Ridden S&P 500 Stocks to Sell Before It's Too Late

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at two upcoming investor conferences. On September 12, 2023, at 10:50 a.m. ET, the Company will present at the Morgan Stanley 21st Annual Global Healthcare Conference. On September 13, 2023, at 7:55 a.m. ET, the Company will present at Baird's 2023 Global Healthc.

Catalent, Inc. to Present at September Investor Conferences

The company delivered a better-than-expected quarterly earnings report. It beat on revenue, and only narrowly missed on earnings.

Why Catalent Stock Zoomed 12% Higher This Week

The headline numbers for Catalent (CTLT) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Catalent (CTLT) Q4 Earnings: A Look at Key Metrics

Some investors might be satisfied with a 5% risk-free return. But those who pick S&P 500 stocks well are doing much better than that.

8 Stocks Turn $10,000 Into $120,005 In 8 Months

Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and its strategic investments.

Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report

The contract drug manufacturer posted steep declines in key fundamentals in its fiscal fourth quarter. Still, it booked more revenue than analysts expected; guidance also topped expectations.

Why Catalent Stock Surged Nearly 5% Higher Today

Catalent, Inc. (NYSE:CTLT ) Q4 2023 Earnings Conference Call August 29, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Greisch - Executive Chair, Board Alessandro Maselli - President and CEO Matti Masanovich - Senior Vice President and CFO Conference Call Participants Tejas Savant - Morgan Stanley David Windley - Jefferies Jacob Johnson - Stephens Jack Meehan - Nephron Research Sean Dodge - RBC Capital Markets John Sourbeer - UBS Justin Bowers - Deutsche Bank Derik De Bruin - Bank of America Max Smock - William Blair Rachel Vatnsdal - J.P. Morgan Tim Daley - Wells Fargo Operator Good morning, ladies and gentlemen.

Catalent, Inc. (CTLT) Q4 2023 Earnings Call Transcript

Catalent (CTLT) records lower revenues in Biologics segment in its fourth-quarter fiscal 2023, resulting in overall soft preliminary performance.

Catalent (CTLT) Preliminary Q4 Revenues Dampened by Lower Sales

Catalent (CTLT) shares surged more than 5% in early trading on Tuesday after the struggling drugmaker secured a deal with activist investor Elliott Investment Management.

Shares of Wegovy Partner Catalent Jump After Striking Deal With Activist Investor Elliott

Catalent Inc is close to a settlement deal with activist investor Elliott Investment Management, which will include the appointment new directors and a pledge to review strategic alternatives such as a sale of the company, Reuters reported, citing sources familiar with the matter.  The media outlet noted the US-based contract drugmaker is set to add four new directors proposed by Elliott to its board, including Elliott's global head of engagement, Steven Barg, a former Goldman Sachs (NYSE:GS) banker, along with former Pfizer chief financial officer Frank D'Amelio.

Catalent nears deal with Elliott Investment Management; will explore company sale

News for Catalent Stock (CTLT)